Ignite Creation Date:
2024-05-06 @ 4:34 PM
Last Modification Date:
2024-10-26 @ 2:12 PM
Study NCT ID:
NCT05027100
Status:
UNKNOWN
Last Update Posted:
2022-07-01
First Post:
2021-08-22
Brief Title:
Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC
Sponsor:
Haibo Zhang
Organization:
Guangzhou University of Traditional Chinese Medicine
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-09-30
Start Date Type:
ACTUAL
Primary Completion Date:
2022-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-06
Completion Date Type:
ESTIMATED
First Submit Date:
2021-08-22
First Submit QC Date:
August 24 2021
Study First Post Date:
2021-08-30
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-06-30
Last Update Post Date:
2022-07-01
Last Update Post Date Type:
ACTUAL